For Research Use Only - Not For Human Consumption
Peptide Stores OnlineResearch Marketplace
← All FDA Peptide News
FDA ApprovalDecember 22, 2025

FDA Approves Wegovy Pill, First Oral GLP-1 Peptide for Obesity

Approved December 22, 2025

On December 22, 2025, the FDA approved the Wegovy pill - a once-daily 25 mg oral semaglutide tablet - for chronic weight management, making it the first oral GLP-1 peptide medicine approved for obesity in the United States.

The approval extends Novo Nordisk’s semaglutide franchise, which already included Ozempic (type 2 diabetes), Rybelsus (oral, type 2 diabetes), and injectable Wegovy (weight management). Each approval is product- and indication-specific: the same molecule carries different labels depending on formulation and dose.

For peptide researchers, the milestone is scientific as much as commercial. Oral delivery of peptides was long considered impractical; the Wegovy pill demonstrates that absorption-enhancer formulations can carry a peptide through full FDA review for a mass-market indication.

The agency’s decision does not extend to compounded semaglutide or any research-grade material - a distinction the FDA has enforced consistently across the GLP-1 category.

Semaglutide

Sources

Frequently Asked Questions

Is there an FDA-approved oral semaglutide for weight management?▾

Yes. On December 22, 2025, the FDA approved the Wegovy pill, a once-daily 25 mg oral semaglutide tablet, for obesity - the first oral GLP-1 peptide medicine for weight management in the US.

How is the Wegovy pill different from Rybelsus?▾

Rybelsus (oral semaglutide) is approved for type 2 diabetes. The Wegovy pill is a higher-dose 25 mg formulation approved specifically for chronic weight management - a distinct product with a distinct indication.

Why does an oral peptide approval matter for researchers?▾

Peptides historically had poor oral bioavailability. Each oral peptide that clears FDA review - first Rybelsus for diabetes, now the Wegovy pill for obesity - validates formulation technologies (like absorption enhancers) that the research field studies closely.

Does this approval cover compounded oral semaglutide?▾

No. The approval applies only to the Wegovy pill product and its labeled indication. Compounded semaglutide products are regulated separately and are not covered by this approval.

Regulatory reporting only. This article describes FDA actions on specific drug products - it is not usage guidance. Peptide Stores Online sells compounds strictly for laboratory research use, not for human consumption.

Related FDA Updates

FDA Approval

FDA Approves MIMRYLO (Rusfertide), First Hepcidin Mimetic Peptide for Polycythemia Vera

August 28, 2026FDA Approval

FDA Approves Foundayo (Orforglipron), First Once-Daily Oral GLP-1 Pill for Weight Management

April 1, 2026Vendor Spotlight

Vendor Spotlight: Ares Research

October 24, 2026

All products listed on Peptide Stores Online are for in-vitro laboratory and educational research purposes only. Not for human or animal consumption. Not evaluated by the Food and Drug Administration. Not intended to diagnose, treat, cure, or prevent any disease or condition. All sellers and buyers agree to full research-use-only terms at account creation. Peptide Stores Online assumes no liability for misuse of any product listed on this platform.